Provides dialysis care and related health services to people with kidney disease, and develops and sells dialysis equipment, supplies and medicines to clinics, hospitals and other treatment providers.
20-F for FY2025, filed Feb 24, 2026
Patients, insurers and government programs pay for dialysis care when treatment is provided. Clinics, hospitals and other customers pay for products when equipment is installed or products are delivered; maintenance and machine-use arrangements bring payments over time.
20-F for FY2025, filed Feb 24, 2026Healthcare services revenue, other than insurance revenues discussed below, are recognized on the date the patient receives treatment and…View ↗
In the healthcare product business, major revenues are generated from the sale of dialysis machines, water treatment systems, home…View ↗
Maintenance is provided over time, and as such revenue is typically recognized on a straight-line basis as the customer is simultaneously…View ↗
A portion of dialysis product revenues is generated from arrangements which give the customer, typically a healthcare provider, the right…View ↗
EUR 19.6B
20-F for FY2025, filed Feb 24, 2026
EUR 19.6B ↗
Treats people with kidney disease at its dialysis clinics and provides services in hospitals; product customers include dialysis clinics, hospitals and other specialized treatment clinics. It sells directly through sales teams and also uses distributors, dealers and agents, with direct-to-patient delivery for home-dialysis products.
20-F for FY2025, filed Feb 24, 2026In the three operating segments, Care Delivery (CD), Value-Based Care (VBC), and Care Enablement (CE), Fresenius Medical Care provides the…View ↗
We also provide dialysis services under contract to hospitals in the U.S. on an “as needed” basis for hospitalized ESRD patients and for…View ↗
We sell most of our products to dialysis clinics, hospitals, and other specialized treatment clinics. A synergistic relationship among our…View ↗
Our distribution network is designed for efficiency, with products moving from factories to central warehouses, then to regional…View ↗
Yes. It kept 5.0% of its revenue as net income in FY2025.
Growing. Revenue grew 11% in 4 years, from EUR 17.6B in FY2021 to EUR 19.6B in FY2025, about 3% a year.
Competes with DaVita, Diaverum, B. Braun, U.S. Renal Care, NephroPlus, Akebia Therapeutics, Ardelyx, Asahi Kasei Medical, Guangdong Biolight Meditech, JMS, Mozarc Medical Holding, Nikkiso, Nipro, Outset Medical, Quanta Dialysis Technologies, Sanofi, Takeda Pharmaceutical, Toray Medical, and Vantive Health
20-F for FY2025, filed Feb 24, 2026Our largest competitors in the dialysis services industry include DaVita, Inc., Diaverum AB, B. Braun SE, U.S. Renal Care, Inc., and…View ↗
Loading...